Q-omics provides the consensus-scored BBS5 profile across patient tissues and cancer cell-line models. BBS5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, BBS5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, BBS5 RNA expression shows 20,662 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, THCA, and ACC as cancer lineages where BBS5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BBS5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BBS5 survival associations across molecular data types. BBS5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BBS5 RNA expression–survival associations across cancer types. High BBS5 expression shows unfavorable associations in LGG and KIRC, but favorable associations in BRCA, SARC, READ and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for BBS5 RNA expression.
This table summarizes BBS5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BBS5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BBS5 shows lower tumor expression in THCA, KICH, KIRC, LUAD and BRCA and higher tumor expression in COAD. The THCA box plot shows higher BBS5 RNA expression in normal versus tumor tissue (log2 FC = −0.302, t-test p < 0.001).
This table shows molecular features associated with BBS5 in patient tissues and cancer cell lines. In patient samples, BBS5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BBS5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
